MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)

MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
Conditions:   Uterine Cervical Neoplasms;   Endometrial Neoplasms;   Squamous Cell Carcinoma of Head and Neck;   Gallbladder Neoplasms;   Cholangiocarcinoma;   Esophageal Neoplasms;   Triple Negative Breast Neoplasms;   Hepatocellular Carcinoma;   Urinary Bladder Neoplasms;   Ovarian Neoplasms;   Stomach Neoplasms
Interventions:   Biological: Pembrolizumab/Vibostolimab Co-Formulation;   Biological: Pembrolizumab;   Drug: Lenvatinib;   Drug: 5-Fluorouracil;   Drug: Cisplatin;   Drug: Paclitaxel;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Docetaxel;   Drug: Bevacizumab;   Drug: Capecitabine;   Drug: Oxaliplatin
Sponsor:   Merck Sharp & Dohme Corp.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

April 28, 2022Comments OffClinicalTrials.gov | Gastroenterology Clinical Trials | Gastroenterology Studies | US National Library of Medicine
Comments